Abstracts

582 – Initiating Long-Acting Lenacapavir in a Cohort of PWH With High Baseline Resistance: A Case Series

Background In 2021, the first long-acting (LA) ART regimen cabotegravir/rilpivirine (CAB/RPV) was approved for people with HIV (PWH) with virologic suppression (VS). Demonstration projects show high rates of achieving VS among PWH with viremia at initiation, leading to US guidelines permitting this approach in 2024. Pre-existing resistance to either CAB or RPV reduces the effectiveness…

337 – Modeling of the Establishment and Dynamics of the Latent Reservoir During Acute HIV/SIV Infection

Background The persistence of a latent viral reservoir is a major barrier to curing Human Immunodeficiency Virus (HIV) infection. Yet, how this reservoir is established and evolves during acute untreated infection remains poorly understood. Methods We developed mathematical models describing the latent reservoir dynamics and fitted them to clinical data from individuals initiating antiretroviral therapy…

649 – Cytomegalovirus IgG Concentrations and Cardiovascular Disease Risk in People With and Without HIV

Background People with HIV have an increased risk of cardiovascular disease (CVD), but the pathogenesis is not fully elucidated. Co-infection with cytomegalovirus (CMV) is associated with CVD, but whether this is explained by traditional CVD risk factors is incompletely understood. We determined associations of CMV IgG seropositivity and concentrations with the burden of traditional CVD…

784 – Population Pharmacokinetics of Rifampin & Pyrazinamide in Patients With TB: The Role of HbA1c & HIV

Background We have previously reported that tuberculosis (TB) patients with poorly controlled diabetes mellitus had a lower risk of adverse drug reactions (ADR), presumably due to low drug concentrations. Here, we focused on the two first-line sterilizing drugs, rifampicin (RIF) and pyrazinamide (PZA), in population pharmacokinetic (PopPK) models in TB patients receiving routine care. Methods…

1060 – Oral PrEP Persistence and Discontinuation in Spain: Insights From a National Multicenter Cohort

Background Oral pre-exposure prophylaxis (PrEP) with TDF/FTC is highly effective in preventing HIV infection, but its impact relies on sustained adherence and persistence. In Spain, PrEP is publicly funded and provided free of charge through the national health system. However, real-world data on PrEP retention and adherence remain limited, and structural challenges may hinder equitable…

876 – Comparing Molecular and Time-Space HIV Cluster Detection Methods in Rural Washington, 2020-2024

Background As part of the “Response” pillar of the Ending the HIV Epidemic Initiative, the CDC requires jurisdictions to use two methods to detect HIV transmission clusters: time-space (TS) and molecular HIV surveillance (MHS). TS methods use spatiotemporal proximity and MHS uses genetic distance. As the proportion of diagnoses in rural areas in Washington state…

899 – Beyond a Binary: Consistency of Transactional Sex Reporting and HIV-Related Risks Among Men

Background Although research on the epidemiology of transactional sex among men has grown, few studies examine this behavior longitudinally. The objective of this study was to examine the prevalence and correlates of transactional sex among men comparing those who reported transactional sex intermittently with those who reported engaging in transactional sex consistently over time. Methods…